NET INCOME (LOSS) PER SHARE

12 Months Ended

Dec. 31, 2014

Earnings Per Share [Abstract]

NET INCOME (LOSS) PER SHARE

NET INCOME (LOSS) PER SHARE

Basic and diluted net income (loss) per share was as follows:

	Years Ended December 31,
	2014		2013			2012
			(As adjusted)*
	(In thousands, except per share amounts)
Basic net income (loss) per share:
Net income (loss)	$	34,004	$	(21,067	)	$	41,204
Weighted average common shares outstanding	32,432		28,416			28,232
Basic net income (loss) per common share	$	1.05	$	(0.74	)	$	1.46
Diluted net income (loss) per share:
Net income (loss)	$	34,004	$	(21,067	)	$	41,204
Weighted average common shares outstanding — Basic	32,432		28,416			28,232
Effect of dilutive securities:
Stock options and restricted stock	528		—			284
Weighted average common shares for diluted earnings per share	32,960		28,416			28,516
Diluted net income (loss) per common share	$	1.03	$	(0.74	)	$	1.44

*See Note 2 of these consolidated financial statements for discussion of the impact of the change in accounting for the medical device excise tax.

Common stock of approximately 0.2 million, 0.7 million and 1.0 million shares at December 31, 2014, 2013 and 2012, respectively, that are issuable through exercise or conversion of dilutive securities were not included in the computation of diluted net income per share because their effect would have been antidilutive.The Company also has warrants outstanding related to its 2016 Notes at December 31, 2014, 2013, and 2012 and the Company's 2016 Notes are convertible to common shares in certain circumstances (see Note 4). These warrants and the excess conversion value of the 2016 Notes are included in the diluted earnings per share calculation using the treasury stock method, unless the effect of including such items would be anti-dilutive.

Performance Shares and Restricted Units that entitle the holders to approximately 0.2 million shares of common stock are included in the basic and diluted weighted average shares outstanding calculation from their date of issuance because no further consideration is due related to the issuance of the underlying common shares.